Screener
Palvella Therapeutics PVLA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 14,313,659 and 12,380,933 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 14 | 12 |
| Additional paid-in capital | 383,421 | 163,338 |
| Accumulated other comprehensive (loss) income | 95 | 83 |
| Accumulated deficit | (151,217) | (135,450) |
| Total stockholders’ equity | 232,313 | 27,983 |
| Total liabilities and stockholders’ equity | $263,759 | $59,559 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's retained earnings?
- Palvella Therapeutics (PVLA) reported retained earnings of -$151.22M in Q1 2026.
- How has Palvella Therapeutics's retained earnings changed year-over-year?
- Palvella Therapeutics's retained earnings decreased by 48.4% year-over-year, from -$101.92M to -$151.22M.
- What is the long-term trend for Palvella Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Palvella Therapeutics's retained earnings has grown at a -8.5% compound annual growth rate (CAGR), from -$211.41M to -$135.45M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Palvella Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude